Effects of Dose Change on the Success of Clinical Trials

Overview

Journal Contemp Clin Trials Commun

Date 2022 Sep 19

PMID 36117568

Authors

Guogen Shan

Aaron Ritter

Justin Miller

Charles Bernick

Affiliations

Soon will be listed here.

Abstract

The search for disease modifying therapies in Alzheimers disease (AD) has recently led to promising results but also revealed design issues in clinical trials themselves. Of particular importance is the potential statistical challenges that can arise when dosages change after an interim analysis, which is not uncommon in contemporary AD trials. Following the recent Aducanumab trials, we sought to study the implications of dose changes on the statistical power of an AD trial. We conducted extensive simulations to calculate statistical power when the relationship between treatment effect size and time is linear or non-linear, and the investigated drug has delayed treatment effect or not. Statistical power depends on many design factors including the dose change time, correlation, population homogeneity, and treatment effect time. We recommend that researchers conduct simulation studies at the interim analysis to justify the modified sample size and/or follow-up time modification meanwhile the type I and II error rates are controlled.

Citing Articles

Sample size calculation for the sequential parallel comparison design with binary endpoint using exact methods.

Shan G, Zhang Y J Appl Stat. 2025; 52(3):656-668.

PMID: 39950014 PMC: 11816656. DOI: 10.1080/02664763.2024.2385997.

Continuity corrected Wilson interval for the difference of two independent proportions.

Shan G, Lou X, Wu S J Stat Theory Appl. 2023; 22(1-2):38-53.

PMID: 37982044 PMC: 10655805. DOI: 10.1007/s44199-023-00054-8.

Response adaptive randomization design for a two-stage study with binary response.

Shan G J Biopharm Stat. 2023; 33(5):575-585.

PMID: 36735855 PMC: 10397367. DOI: 10.1080/10543406.2023.2170399.

Monte Carlo cross-validation for a study with binary outcome and limited sample size.

Shan G BMC Med Inform Decis Mak. 2022; 22(1):270.

PMID: 36253749 PMC: 9578204. DOI: 10.1186/s12911-022-02016-z.

References

Miller J, Shan G, Lombardo J, Jimenez-Maggoria G . Biomedical informatics applications for precision management of neurodegenerative diseases. Alzheimers Dement (N Y). 2018; 4:357-365. PMC: 6118097. DOI: 10.1016/j.trci.2018.03.007. View

Clifton L, Birks J, Clifton D . Comparing different ways of calculating sample size for two independent means: A worked example. Contemp Clin Trials Commun. 2018; 13:100309. PMC: 6297128. DOI: 10.1016/j.conctc.2018.100309. View

Shan G . Sample size calculation for agreement between two raters with binary endpoints using exact tests. Stat Methods Med Res. 2016; 27(7):2132-2141. DOI: 10.1177/0962280216676854. View

Fillit H, Green A . Aducanumab and the FDA - where are we now?. Nat Rev Neurol. 2021; 17(3):129-130. DOI: 10.1038/s41582-020-00454-9. View

Cummings J, Salloway S . Aducanumab: Appropriate use recommendations. Alzheimers Dement. 2021; 18(3):531-533. PMC: 8792094. DOI: 10.1002/alz.12444. View

Bernick C, Cummings J, Raman R, Sun X, Aisen P . Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol. 2012; 69(7):901-5. DOI: 10.1001/archneurol.2011.3758. View

Lakens D . Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013; 4:863. PMC: 3840331. DOI: 10.3389/fpsyg.2013.00863. View

Schneider L . A resurrection of aducanumab for Alzheimer's disease. Lancet Neurol. 2020; 19(2):111-112. DOI: 10.1016/S1474-4422(19)30480-6. View

Sabbagh M, Cummings J . Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019". Alzheimers Dement. 2020; 17(4):702-703. PMC: 8043968. DOI: 10.1002/alz.12235. View

10.

Shan G, Wang W . Advanced statistical methods and designs for clinical trials for COVID-19. Int J Antimicrob Agents. 2021; 57(1):106167. PMC: 7833547. DOI: 10.1016/j.ijantimicag.2020.106167. View

11.

Wilding G, Consiglio J, Shan G . Exact approaches for testing hypotheses based on the intra-class kappa coefficient. Stat Med. 2014; 33(17):2998-3012. DOI: 10.1002/sim.6135. View

12.

Le Tourneau C, Lee J, Siu L . Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009; 101(10):708-20. PMC: 2684552. DOI: 10.1093/jnci/djp079. View

13.

Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S . Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther. 2021; 13(1):98. PMC: 8111757. DOI: 10.1186/s13195-021-00838-z. View

14.

Sevigny J, Chiao P, Bussiere T, Weinreb P, Williams L, Maier M . The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016; 537(7618):50-6. DOI: 10.1038/nature19323. View

15.

Shan G, Gerstenberger S . Fisher's exact approach for post hoc analysis of a chi-squared test. PLoS One. 2017; 12(12):e0188709. PMC: 5737889. DOI: 10.1371/journal.pone.0188709. View

16.

Wilding G, Shan G, Hutson A . Exact two-stage designs for phase II activity trials with rank-based endpoints. Contemp Clin Trials. 2011; 33(2):332-41. DOI: 10.1016/j.cct.2011.10.008. View

17.

Todd S, Whitehead A, Stallard N, Whitehead J . Interim analyses and sequential designs in phase III studies. Br J Clin Pharmacol. 2001; 51(5):394-9. PMC: 2014474. DOI: 10.1046/j.1365-2125.2001.01382.x. View

18.

Shan G . Optimal two-stage designs based on restricted mean survival time for a single-arm study. Contemp Clin Trials Commun. 2021; 21:100732. PMC: 7856426. DOI: 10.1016/j.conctc.2021.100732. View

19.

Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K . Alzheimer's disease drug development pipeline: 2019. Alzheimers Dement (N Y). 2019; 5:272-293. PMC: 6617248. DOI: 10.1016/j.trci.2019.05.008. View

20.

Shan G, Zhang H . Two-stage optimal designs with survival endpoint when the follow-up time is restricted. BMC Med Res Methodol. 2019; 19(1):74. PMC: 6448233. DOI: 10.1186/s12874-019-0696-x. View